Skip to main content
Luye Pharma Group Limited logo

Luye Pharma Group Limited — Investor Relations & Filings

Ticker · 2186 HKEX Manufacturing
Open in API
Filings indexed 1,503 across all filing types
Latest filing 2024-11-01 Capital/Financing Update
Country HK Hong Kong
Listing HKEX 2186

About Luye Pharma Group Limited

http://www.luye.cn

Luye Pharma Group is an international pharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative medications, novel formulations, and biopharmaceutical products. The company's core strategy emphasizes advanced drug delivery systems, including microspheres, liposomes, and transdermal technologies, to enhance therapeutic efficacy and patient compliance. Luye Pharma maintains a strong focus on key therapeutic areas, particularly the Central Nervous System (CNS). Its portfolio includes proprietary products such as Roxinlin® (Toludesvenlafaxine extended-release tablets) and various long-acting injectable antipsychotic formulations, positioning the group as a global pharmaceutical enterprise.

Recent filings

Filing Released Lang Actions
OVERSEAS REGULATORY ANNOUNCEMENT
Capital/Financing Update Classification · 95% confidence The document is an announcement from Luye Pharma Group Ltd. regarding the issuance of US$100,000,000 5.85% convertible bonds due 2025 (Tranche A Bonds). It references previous announcements and includes an attached Information Memorandum dated 28 October 2024. The document is issued pursuant to Rule 13.10B of the Listing Rules and is described as an "Overseas Regulatory Announcement." The text emphasizes that the Information Memorandum is not a prospectus or invitation to the public but is for information dissemination and compliance purposes. The document is lengthy (15,000 characters) and contains detailed disclaimers and legal notices about the offering and distribution restrictions, typical of capital raising or financing announcements. There is no indication that this is a full financial report, earnings release, or management discussion. Instead, it is an update related to the company's capital raising activity via convertible bonds. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2024-11-01 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2024
Regulatory Filings Classification · 95% confidence The document is a detailed monthly return report for movements in securities, specifically for Luye Pharma Group Ltd., submitted to the Hong Kong Exchanges and Clearing Limited. It includes information on authorized share capital, issued shares, treasury shares, convertible bonds, and confirmations related to compliance with listing rules. The document is structured as a regulatory submission with no financial statements or management discussion, and it primarily reports on share capital movements and confirmations. It is not an annual or interim report, earnings release, or any form of management or audit report. The document fits the profile of a regulatory filing reporting share capital and securities movements under exchange rules, which is typical for the Regulatory Filings (RNS) category as a fallback for miscellaneous compliance reports that do not fit other categories.
2024-11-01 English
COMPLETION OF THE ISSUE OF US$100,000,000 5.85 PER CENT. CONVERTIBLE BONDS DUE 2025
Capital/Financing Update Classification · 100% confidence The document is an announcement regarding the completion of the issue of US$100,000,000 5.85% convertible bonds due 2025 by Luye Pharma Group Ltd. It references previous announcements and details the terms and expected listing date of the bonds. The content focuses on financing activities, specifically the issuance of convertible bonds, which is a capital raising event. The document is about the completion of a financing transaction and does not contain financial statements or detailed financial performance data. It is not a full report but an update on capital structure changes. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is 4858 characters, which is consistent with an announcement rather than a full report.
2024-10-30 English
CHANGE OF CLOSING DATE OF THE ISSUE OF US$100,000,000 5.85 PER CENT. CONVERTIBLE BONDS DUE 2025
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding a change in the closing date for the issuance of convertible bonds by Luye Pharma Group Ltd. It references a previous announcement about the bond issuance and provides updated information on the closing date. The content focuses on financing activity, specifically the issuance of convertible bonds, which is a capital raising event. The document is relatively short (3490 characters) and is an announcement rather than a full report or detailed financial statement. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2024-10-28 English
PROPOSED ISSUE OF US$100,000,000 5.85 PER CENT. CONVERTIBLE BONDS DUE 2025 AND US$50,000,000 5.85 PER CENT. CONVERTIBLE BONDS DUE 2025
Capital/Financing Update Classification · 100% confidence The document is an announcement from Luye Pharma Group Ltd. regarding the proposed issue of US$100 million and US$50 million 5.85% convertible bonds due 2025. It details the subscription agreements, conditions precedent, termination clauses, and listing applications for the bonds and conversion shares. The content focuses on the company's fundraising and capital raising activities through convertible bonds. There are no financial statements or quarterly/yearly financial results presented, nor is this a transcript, management report, or legal proceeding update. The document is a detailed announcement about a capital raising transaction, specifically the issuance of convertible bonds. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), indicating it is not a mere brief announcement or report publication notice but a full announcement of financing activity.
2024-10-23 English
Monthly Return of Equity Issuer on Movements in Securities
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 30 September 2024. It details movements in authorised/registered share capital, issued shares, treasury shares, share options, and confirms compliance with listing rules. There is no financial performance data, earnings information, or management discussion. The document is a regulatory filing related to share capital movements and compliance confirmations submitted to the Hong Kong Exchanges and Clearing Limited. It fits the category of Regulatory Filings (RNS) as it is a compliance and disclosure document rather than a financial report or announcement of a report.
2024-10-02 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.